Authors : Musa Dauda Kwanchi; Ronas Richard; Male. Sale Mohammed

Volume/Issue : Volume 10 - 2025, Issue 7 - July

Google Scholar : https://tinyurl.com/52dnpmah

Scribd : https://tinyurl.com/3ck9252x

DOI : https://doi.org/10.38124/ijisrt/25jul1542

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : This study is use to Assessment of Caregivers’ Knowledge and Acceptance of the Human Papilloma Virus Vaccine in Maihula Community, Bali LGA, Taraba State, Nigeria. Human papilloma virus is a significant cause of certain cancer such as anal cancer, cervical cancer and genital warts etc. and vaccinating is a means of preventing the occurrence. The objective of this study is to assess the level of knowledge among care givers, to determine the level of awareness among care givers and to identify factors influencing knowledge and acceptance of HPV among care givers. In order to achieve this objectives above, the research employed a descriptive survey design. The sample size was 222 respondents, selected through simple random sampling. Data were collected using a structured questionnaire and analyzed using frequency tables, percentages, and Chi-square tests to determine associations. Findings revealed that 67.5% of respondents had heard of HPV, and 86.7% were aware of the HPV vaccine. Furthermore, 72.1% expressed willingness to vaccinate their children, and 65.3% believed the benefits of the vaccine outweighed the risks, though only 36.0% had vaccinated their children. Cost, family influence, and fear of side effects were identified as key barriers to vaccine acceptance. The test of association showed that educational level was significantly associated with knowledge of the HPV vaccine (p = 0.001), while sex (p = 0.041), age (p = 0.002), and educational level (p = 0.000) were significantly associated with acceptance of the vaccine. Female caregivers, younger respondents, and those with higher education were more likely to accept the vaccine, whereas occupation showed no significant association with either knowledge or acceptance. The study concludes that while knowledge and acceptance of the HPV vaccine are generally high, targeted health education for less-educated and older caregivers is essential to improve vaccine uptake. It recommends strengthening community sensitization, subsidizing vaccine costs, and leveraging healthcare providers to address misconceptions.

References :

1. American Cancer Society. (1996). Estimated incidence of cervical cancer in the United States. CA: A Cancer Journal for Clinicians, 46(1), 1–6.
2. Anthony, S. J., et al. (2021). HPV vaccination program implementation in Nigeria. Vaccine, 39(29), 3882–3891. https://doi.org/10.1016/j.vaccine.2021.05.065
3. Biswas, A., et al. (2021). Prevalence of high-risk HPV types in Kerala and implications for vaccine effectiveness. Indian Journal of Medical Research, 153(2), 239–246. https://doi.org/10.4103/ijmr.IJMR_3452_19
4. Bonati, L., et al. (2015). Global epidemiology of cervical cancer and HPV. Journal of Global Oncology, 1(3), 122–131. https://doi.org/10.1200/JGO.2014.001084
5. Brewer, N. T., Fazekas, K. I., & Rimer, B. K. (2011). Vaccine uptake among diverse populations: A review of recent studies. Vaccine, 29(24), 3997–4002. https://doi.org/10.1016/j.vaccine.2011.03.027
6. Brooke, S., et al. (2014). HPV types and their role in cervical and other cancers. Cancer Epidemiology, 38(4),328–334. https://doi.org/10.1016/j.canep.2014.06.005
7. Bruni, L. (2021). Analysis of WHO/UNICEF HPV vaccination coverage and progress towards 2030 targets. Vaccine, 39(16), 2224–2230. https://doi.org/10.1016/j.vaccine.2021.02.002
8. Castellsagué, X. (2008). HPV types and their role in cervical cancer and other malignancies. Current Opinion in Oncology, 20(5), 498–503. https://doi.org/10.1097/CCO.0b013e32830f846a
9. CDC (Centers for Disease Control and Prevention). (2016). HPV types and their association with cancers. Morbidity and Mortality Weekly Report, 65(3), 1–9. https://doi.org/10.15585/mmwr.mm6530a1
10. Cernuschi, T. (2015). Gavi HPV demonstration program and findings. Vaccine, 33(32), 3690–3698. https://doi.org/10.1016/j.vaccine.2015.06.067
11. Cook, R. L., et al. (2016). Racial disparities in HPV vaccine initiation among adolescent girls in the United States. Journal of Adolescent Health, 58(3), 295–303. https://doi.org/10.1016/j.jadohealth.2015.10.229
12. Dunne, E. F. (2013). Human papillomavirus (HPV) infection: Clinical consequences and prevention. Journal of Clinical Virology, 57(1), 8–16. https://doi.org/10.1016/j.jcv.2013.03.009
13. Emeribe, A. U. (2021). HPV prevalence in Nigeria and associated risk factors. African Journal of Reproductive Health, 25(3), 41–49. https://doi.org/10.29063/ajrh2021/v25i3.5
14. Ezenwa, A., et al. (2019). HPV vaccination campaign and its progress in Nigeria. Nigerian Journal of Clinical Practice, 22(4), 515–523. https://doi.org/10.4103/njcp.njcp_171_19
15. Forman, D., et al. (2021). Global cervical cancer statistics. The Lancet Oncology, 22(2), 224–235. https://doi.org/10.1016/S1470-2045 (20)30561-0
16. Garland, S. M., & Smith, J. M. (2010). HPV vaccination: Dosage and administration. Vaccine, 28(3), 628–634. https://doi.org/10.1016/j.vaccine.2009.11.086
17. Gerend, M. A., & Bland, K. A. (2015). Association between parents’ education and HPV vaccine uptake. Vaccine, 33(28), 3271–3276. https://doi.org/10.1016/j.vaccine.2015.05.021
18. Gillison, M. L. (2023). Structural variations in HPV-related cancers. Nature Reviews Clinical Oncology, 20(4), 232–248. https://doi.org/10.1038/s41571-023-00748-1
19. Kimple, R. J. (2015). HPV-related head and neck cancers and their prognosis. Head & Neck, 37(2), 275–281. https://doi.org/10.1002/hed.23847
20. Koutsky, L. A. (2014). Prevalence of genital HPV infection among sexually active women. American Journal of Epidemiology, 179(9), 1013–1020. https://doi.org/10.1093/aje/kwu011
21. Lai, J., et al. (2011). HPV vaccination recommendations and funded programs: An overview. Vaccine, 29(47), 8402–8410. https://doi.org/10.1016/j.vaccine.2011.08.046\
22. Mischianu, I. (2021). HPV vaccination benefits and challenges for men. Human Vaccines & Immunotherapeutics, 17(5), 1463–1470. https://doi.org/10.1080/21645515.2021.1894695
23. Royal Marsden. (2019). Risk and development timeline of cervical cancer due to HPV. Clinical Oncology, 31(5), 284–291. https://doi.org/10.1016/j.clon.2018.12.005
24. Skinner, C. S., & Cooper, T. (2011). School-based HPV vaccination programs: Efficacy and challenges. Journal of School Health, 81(9), 505–513. https://doi.org/10.1111/j.1746-1561.2011.00623.x
25. Watson, M. (2018). Discussion on the introduction of HPV vaccination in various income countries. Global Health Action, 11(1), 1436655. https://doi.org/10.1080/16549716.2018.1436655